Invitrogen, Flush from Acquisition Flurry, Flirts with Novel Ad Campaigns and Promises Rejuvenated R&D | GenomeWeb

NEW YORK, Dec. 3 – Invitrogen, poised to post supercharged revenue and profit for the current fiscal year, said it will investigate running advertising in non-traditional scientific markets, and intends to revive slumping research and development spending by 2003.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.